Insider Selling: Chemed Co. (NYSE:CHE) EVP Sells 2,143 Shares of Stock

Chemed Co. (NYSE:CHE) EVP Spencer S. Lee sold 2,143 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $495.67, for a total transaction of $1,062,220.81. Following the completion of the transaction, the executive vice president now directly owns 22,959 shares of the company’s stock, valued at approximately $11,380,087.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

NYSE CHE opened at $494.17 on Wednesday. Chemed Co. has a 52 week low of $330.01 and a 52 week high of $528.29. The company has a 50 day moving average price of $501.92 and a 200 day moving average price of $457.67. The firm has a market cap of $7.87 billion, a PE ratio of 31.06, a price-to-earnings-growth ratio of 3.17 and a beta of 0.66.

Chemed (NYSE:CHE) last issued its quarterly earnings results on Wednesday, July 29th. The company reported $4.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.75 by $0.66. Chemed had a return on equity of 36.71% and a net margin of 12.99%. The business had revenue of $502.20 million for the quarter, compared to the consensus estimate of $522.90 million. During the same period in the prior year, the firm posted $3.36 earnings per share. The business’s quarterly revenue was up 6.0% on a year-over-year basis. Analysts anticipate that Chemed Co. will post 16.14 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 4th. Stockholders of record on Monday, August 17th were issued a dividend of $0.34 per share. The ex-dividend date of this dividend was Friday, August 14th. This represents a $1.36 annualized dividend and a dividend yield of 0.28%. This is an increase from Chemed’s previous quarterly dividend of $0.32. Chemed’s dividend payout ratio is 9.75%.

Separately, Zacks Investment Research raised Chemed from a “hold” rating to a “buy” rating and set a $489.00 target price on the stock in a research report on Tuesday, May 19th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $512.25.

Hedge funds have recently added to or reduced their stakes in the stock. Credit Agricole S A acquired a new stake in shares of Chemed in the first quarter worth $34,000. Citizens Financial Group Inc RI acquired a new stake in Chemed during the first quarter worth about $41,000. BDO Wealth Advisors LLC purchased a new position in Chemed during the first quarter valued at approximately $43,000. Private Capital Group LLC acquired a new position in Chemed in the first quarter valued at approximately $44,000. Finally, Tower Research Capital LLC TRC boosted its position in Chemed by 348.3% in the 1st quarter. Tower Research Capital LLC TRC now owns 130 shares of the company’s stock worth $57,000 after purchasing an additional 101 shares in the last quarter. Institutional investors own 90.55% of the company’s stock.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations.

Featured Story: Benefits of owning preferred stock

Insider Buying and Selling by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.